Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial

(2018) Burkhard Möller et al.   ARTHRITIS CARE & RESEARCH

Rheumatoid arthritis

(2018) Josef S. Smolen et al.   Nature Reviews Disease Primers

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

(2017) Peter C. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

The impact of smoking on disease activity, disability, and radiographic damage in rheumatoid arthritis: is cigarette protective?

(2017) Mario Andrés Quintana-Duque et al.   RHEUMATOLOGY INTERNATIONAL

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

(2016) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erosive and osteoarthritic structural progression in early rheumatoid arthritis

(2016) Daniel F. McWilliams et al.   RHEUMATOLOGY

T cell migration in rheumatoid arthritis

(2015) Mario Mellado   Frontiers in Immunology

How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

(2014) Roy Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial

(2014) Karen Hambardzumyan et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

(2014) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Early Local Swelling and Tenderness Are Associated with Large-joint Damage After 8 Years of Treatment to Target in Patients with Recent-onset Rheumatoid Arthritis

(2013) M. van den Broek et al.   JOURNAL OF RHEUMATOLOGY

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice

(2012) Jaclyn Anderson et al.   ARTHRITIS CARE & RESEARCH

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors

(2011) M. G. Bonilla-Hernan et al.   RHEUMATOLOGY

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic?

(2010) D. P. C. de Rooy et al.   RHEUMATOLOGY

MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)

(2008) M L Hetland et al.   ANNALS OF THE RHEUMATIC DISEASES